CMX157

ContraVir Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	CMX157
Also known as	lipid conjugate TFV(tenofovir), Lipid Conjugate TFV
Sponsor	ContraVir Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2, Multiple Ascending Dose Proof of Concept Study (PHASE2)
A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects (PHASE1)
A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CMX157 CI brief — competitive landscape report
CMX157 updates RSS · CI watch RSS
ContraVir Pharmaceuticals, Inc. portfolio CI